Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

AMAG Pharmaceuticals: Trying to Project 2019 Sales for the Makena Franchise (AMAG, $24.45, Buy)

Investment Thesis

The investment outlook for AMAG in 2019 is primarily about Makena and this report focuses almost entirely on how…
Read more…

Antares: AMAG Submits Supplemental New Drug Application to FDA for Makena« Auto-Injector for Subcutaneous Use: (Antares (ATRS, Buy, $2.86)

AMAG announced on April17, 2017 that it had submitted a sNDA for the Makena Auto-Injector. This was in line with…
Read more…